A Phase II study to assess the safety and efficacy of TGR-1202 in patients with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy
Sponsor: |
TG Therapeutics |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAQ8698 |
U.S. Govt. ID: |
NCT02742090 |
Contact: |
Nicole Lamanna: 646-317-5205 / nl2129@cumc.columbia.edu |
This study is being done to see how well tolerated the investigational drug TGR-1202 is in comparison to other similar therapeutics agents in treating patients with chronic lymphocytic leukemia (CLL).
This study is closed
Investigator
Nicole Lamanna, MD
Do you have a confirmed diagnosis of CLL? |
Yes |
No |